NeurAxis Announces Expanded Insurance Coverage for Groundbreaking Neuromodulation Therapy
CARMEL, Ind., June 17, 2025 – NeurAxis, Inc., a medical technology company pioneering neuromodulation therapies for chronic conditions, today announced significant medical policy coverage for its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. Two major health insurers in Connecticut and Massachusetts, covering approximately 700,000 members, have approved coverage for PENFS, bringing NeurAxis’ total national coverage to roughly 53 million members.
NeurAxis’ PENFS technology, known as IB-Stim, has received FDA clearance for treating functional abdominal pain associated with irritable bowel syndrome (IBS) and Pediatric Functional Dyspepsia in adolescents aged 8-21. This non-surgical device works by delivering gentle electrical impulses to cranial nerve bundles in the ear. Notably, there are currently no FDA-approved drug therapies available for children suffering from abdominal pain-related disorders of the gut-brain interaction. Off-label prescription drugs are often prescribed despite limited evidence of their effectiveness and potential serious side effects.
“We’re focused on expanding insurance coverage for IB-Stim to make this critical therapy more accessible and affordable for patients suffering from abdominal pain associated with IBS and Pediatric Functional Dyspepsia,” said Brian Carrico, CEO of NeurAxis. “This development marks an exciting inflection point for NeurAxis. Our proprietary PENFS technology has been incorporated into the leading pediatric academic society’s treatment guidelines for Functional Abdominal Pain in IBS, a key milestone that we expect will drive broader policy coverage and reimbursement.”
The upcoming activation of a Category I CPT code for PENFS, effective January 1, 2026, is expected to further enhance the therapy’s adoption by assigning value to the procedure and improving reimbursement rates. With a recently strengthened balance sheet, NeurAxis is well-positioned to capitalize on the growing demand for its innovative therapy.
About NeurAxis, Inc.
NeurAxis, Inc. is a medical technology company dedicated to developing neuromodulation therapies for chronic and debilitating conditions affecting both children and adults. The company is committed to advancing scientific research and promoting evidence-based medicine to drive adoption of its IB-Stim therapy among medical professionals, scientists, and patients. In addition to its cleared indications, NeurAxis is currently conducting clinical trials exploring the potential of PENFS in various pediatric and adult conditions with significant unmet healthcare needs.
Forward-Looking Statements
Certain statements in this press release are forward-looking and subject to risks and uncertainties. These statements reflect management’s current assumptions and expectations about future events and trends that may impact NeurAxis’ business, strategy, operations, or financial performance. Actual results may differ materially due to various factors, including economic conditions, stock price volatility, clinical trial outcomes, and regulatory developments. For more information on risk factors, please refer to NeurAxis’ public filings with the Securities and Exchange Commission.
For more information about NeurAxis and its therapies, please visit NeurAxis’ website.
